Pharmaceutically active 9-chloroprostaglandins
    2.
    发明授权
    Pharmaceutically active 9-chloroprostaglandins 失效
    药用活性9-氯前列腺素

    公开(公告)号:US5204371A

    公开(公告)日:1993-04-20

    申请号:US792574

    申请日:1991-11-15

    IPC分类号: C07C405/00

    CPC分类号: C07C405/0041 C07C405/00

    摘要: Compounds of the formula ##STR1## wherein the 9-chlorine atom can be in the .alpha.-or .beta.-position,A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2,--, trans--CH.dbd.CH--, or --CH.tbd.C--, W is hydroxymethylene orD and E together represent a direct bond orD is a straight-chain or branched alkylene group of 1-10 carbon atoms, optionally substituted by fluorine, andE is oxygen or sulfur or a direct bond, andR.sub.4 is hydroxy or hydroxy etherified or esterified as defined for W above;R.sub.5 is a C.sub.1-10 hydrocarbon aliphatic group; a C.sub.1-10 hydrocarbon aliphatic group substituted by aryl, a substituted aryl as defined for R.sub.2 above, or halogen; or cycloalkyl, substituted cycloalkyl, aryl, substituted aryl or aromatic heterocyclic, all as defined for R.sub.2 above;or a physiologically acceptable salt thereof with a base when R.sub.1 is OH,have valuable pharmacologoical properties.

    摘要翻译: 其中9-氯原子可以是α-或β-位的式为“IMAGE”的化合物,A为-CH 2 -CH 2 - 或顺式-CH = CH-,B为-CH 2 -CH 2, - , CH = CH-或-CH 3 B - ,W是羟基亚甲基或D和E一起代表直接键,或D是1-10个碳原子的直链或支链亚烷基,任选被氟取代,E是 氧或硫或直接键,并且R4是如上定义的羟基或羟基醚化或酯化; R5是C1-10烃脂族基团; 被芳基取代的C1-10烃脂族基,对上述R2定义的取代芳基或卤素; 或环烷基,取代的环烷基,芳基,取代的芳基或芳族杂环,全部如上述R2所定义; 或其生理上可接受的盐,当R1为OH时,具有有价值的药理学性质。

    Pharmaceutically active 9-chloroprostaglandins
    3.
    发明授权
    Pharmaceutically active 9-chloroprostaglandins 失效
    药用活性9-氯前列腺素

    公开(公告)号:US4444788A

    公开(公告)日:1984-04-24

    申请号:US387140

    申请日:1982-06-10

    CPC分类号: C07C405/00 C07C405/0041

    摘要: Compounds of the formula ##STR1## wherein the 9-chlorine atom can be in the .alpha.- or .beta.-position,R.sub.1 is OR.sub.2, or NHR.sub.3 wherein R.sub.3 is H or the acyl group ofa C.sub.1-15 hydrocarbon carboxylic or sulfonic acid;A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2 --,trans--CH.dbd.CH--, or --C.tbd.C--, ##STR2## wherein the OH-group in each case can be in the .alpha.- or .beta.-position, and can be etherified or esterified by tetrahydropyranyl, tetrahydrofuranyl, .alpha.-ethoxyethyl, trimethylsilyl dimethyl, tert-butylsilyl, tribenzylsilyl, acetyl, propionyl, butyryl or benzoyl;D and E together represent a direct bond orD is a straight-chain or branched alkylene group of 1-10 carbon atoms, optionally substituted by fluorine, andE is oxygen or sulfur or a direct bond, andR.sub.4 is hydroxy or hydroxy etherified or esterified as defined for W above;R.sub.5 is a C.sub.1-10 hydrocarbon aliphatic group; a C.sub.1-10 hydrocarbon, aliphatic group substituted by aryl, a substituted aryl as defined for R.sub.2 above, or halogen; or cycloalkyl, substituted cycloalkyl, aryl, substituted aryl or aromatic heterocyclic, all as defined for R.sub.2 above;or a physiologically acceptable salt thereof with a base when R.sub.1 is OH,have valuable pharmacological properties.

    摘要翻译: 其中9-氯原子可以是α-或β-位,R1是OR2或NHR3,其中R3是H或C1-15烃羧酸或磺酸的酰基; A是-CH 2 -CH 2 - 或顺式-CH = CH-,B是-CH 2 -CH 2 - ,反式-CH = CH-或-C 3位C,,其中每种情况下的OH-基团可以是 四氢呋喃基,α-乙氧基乙基,三甲基甲硅烷基二甲基,叔丁基甲硅烷基,三苄基甲硅烷基,乙酰基,丙酰基,丁酰基或苯甲酰基可以醚化或酯化。 D和E一起代表直接键或D是1-10个碳原子的直链或支链亚烷基,任选被氟取代,E是氧或硫或直接键,并且R 4是羟基或羟基醚化或 酯化如上述W所定义; R5是C1-10烃脂族基团; C1-10烃基,被芳基取代的脂族基团,对上述R2定义的取代芳基或卤素; 或环烷基,取代的环烷基,芳基,取代的芳基或芳族杂环,全部如上述R2所定义; 或其生理上可接受的盐,当R1为OH时,具有有价值的药理学性质。

    Novel carbacyclins, processes for their production and their use as
medicinal agents
    4.
    发明授权
    Novel carbacyclins, processes for their production and their use as medicinal agents 失效
    新型碳霉素,其生产工艺及其作为药剂的使用

    公开(公告)号:US4827017A

    公开(公告)日:1989-05-02

    申请号:US21102

    申请日:1987-03-03

    CPC分类号: C07C405/0083

    摘要: Carbacyclin derivatives of Formula I ##STR1## wherein R.sub.1 is OR.sub.2 wherein R.sub.2 is hydrogen, C.sub.1 -C.sub.10 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl, C.sub.6 -C.sub.10 -aryl, ##STR2## or a heterocyclic residue, or R.sub.1 is R.sub.3 wherein R.sub.3 is C.sub.1 -C.sub.10 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl, C.sub.6 -C.sub.10 -aryl, C.sub.7 -C.sub.14 -aralkyl or a heterocyclic residue,A is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C--,W is a free or functionally modified hydroxymethylene group or a free or functionally modified ##STR3## wherein the OH-group can be in the .alpha.- or .beta.-position, D is ##STR4## a straight-chain, saturated alkylene group of 1-10 carbon atoms, or a branched, saturated or a straight-chain or branched, unsaturated alkylene group of 2-10 carbon atoms, each of which can optionally by substituted by fluorine atoms,n is the number 1, 2 or 3,E is --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 -- wherein R.sub.6 and R.sub.7 differ from each other and one is hydrogen and the other alkyl of 1-5 carbon atoms, or one is hydrogen and the other is halogen, orE can also be --CH.sub.2 CH.sub.2 -- when R.sub.1 is R.sub.3,R.sub.4 is C.sub.1-10 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl, optionally substituted C.sub.6 -C.sub.10 -aryl or a heterocyclic group,R.sub.5 is a free or functionally modified hydroxy group and, when R.sub.2 is hydrogen, the salts thereof with physiologically compatible bases;are useful as medicinal agents.

    摘要翻译: 式I的卡巴环素衍生物其中R 1是OR 2,其中R 2是氢,C 1 -C 10 - 烷基,C 3 -C 10 - 环烷基,C 6 -C 10 - 芳基,或者杂环残基,或者R 1是R 3 其中R 3是C 1 -C 10 - 烷基,C 3 -C 10 - 环烷基,C 6 -C 10 - 芳基,C 7 -C 14 - 芳烷基或杂环残基,A是-CH 2 -CH 2 - ,反式-CH = CH-或-C - ,W是游离或官能改性的羟基亚甲基或游离的或功能上被修饰的“IMAGE”,其中OH基可以是α或β-位,D是直链,饱和的亚烷基 1-10个碳原子,或2-10个碳原子的支链,饱和或直链或支链不饱和的亚烷基,其各自可任选被氟原子取代,n为数1,2或3, E是-C 3位C或-CR 6 = CR 7 - ,其中R 6和R 7彼此不同,一个是氢,1-5个碳原子的另一个烷基,或一个是氢,另一个是卤素,或者也可以是 当R 1为R 3,R 4为C 1-10时为-CH 2 CH 2 - 烷基,C 3 -C 10 - 环烷基,任选取代的C 6 -C 10 - 芳基或杂环基,R 5是游离或官能改性的羟基,并且当R 2是氢时,其与生理上相容的碱的盐; 作为药剂有用。

    Certain 5-cyano-16-fluoro-prostacyclins and their use as pharmaceuticals
    5.
    发明授权
    Certain 5-cyano-16-fluoro-prostacyclins and their use as pharmaceuticals 失效
    某些5-氰基-16-氟前列环素及其作为药物的用途

    公开(公告)号:US4378370A

    公开(公告)日:1983-03-29

    申请号:US309967

    申请日:1981-10-06

    摘要: Prostacyclin derivatives of the formula ##STR1## wherein R.sub.1 is OR.sub.3 wherein R.sub.3 is hydrogen or alkyl of 1-10 carbon atoms, or R.sub.1 is NHR.sub.4 wherein R.sub.4 is alkanoyl or alkanesulfonyl,B is alkylene of 1-5 carbon atoms,A is --CH.sub.2 --CH.sub.2 --, cis--CH.dbd.CH--, or trans--CH.dbd.CH--,W is hydroxymethylene or ##STR2## wherein the OH-group is optionally substituted by alkanoyl of 1-4 carbon atoms and the free or substituted OH-group can be in the .alpha.- or .beta.- position,R.sub.2 is alkyl of 1-6 carbon atoms optionally substituted by phenyl, or R.sub.2 is phenyl,R.sub.5 is hydroxy optionally substituted by alkanoyl of 1-4 carbon atoms,R.sub.6 is hydrogen, fluorine, or alkyl of 1-4 carbon atomsor when R.sub.3 is hydrogen, a salt thereof with a physiologically compatible base,have pharmacological activity e.g., blood pressure-lowering and bronchodilatory effects.

    摘要翻译: PCT No.PCT / DE81 / 00031 Sec。 371日期1981年10月6日 102(e)日期1981年10月6日PCT提交1981年2月5日PCT公布。 出版物WO81 / 02296 日本1981年8月20日。其中R 1为OR 3的式(I)其中R 3为氢或1-10个碳原子的烷基,或R 1为NHR 4,其中R 4为烷酰基或链烷磺酰基,B为1- 5个碳原子,A是-CH 2 -CH 2 - ,顺式-CH = CH-或反式-CH = CH-,W是羟基亚甲基或其中OH基任选被1-4个碳原子的烷酰基取代 并且游离或取代的OH基团可以在α或β位,R 2是任选被苯基取代的1-6个碳原子的烷基,或者R 2是苯基,R 5是任选被1-4碳的烷酰基取代的羟基 原子,R6是氢,氟或1-4个碳原子的烷基,或当R3是氢时,其与生理上相容的碱的盐具有药理活性,例如降血压和支气管扩张作用。